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Abstract
We investigated the presence of autoantibodies to baculovirus-
expressed human recombinant 65- and 67-kD isoforms of glu-
tamate decarboxylase (GAD65 and GAD67) in insulin-depen-
dent diabetes mellitus (IDDM). In the immunoprecipitation
test using I35Slmethionine-labeled GADs antibodies to GAD65
were detected in 13/15 (87%) islet cell antibody (ICA)-posi-
tive and in 1/35 (2.9%) ICA-negative first-degree relatives of
patients with IDDM, in 6/11 (54.5%) ICA-positive nondia-
betic schoolchildren, and in 35/50 (70%) patients with newly
diagnosed IDDM. GAD67 antibodies were positive only in five
(33%) of the ICA-positive relatives (P < 0.05) and in nine
(18%) IDDM patients at onset (P < 0.00001). After onset of
IDDM antibodies to GAD65 and GAD67 declined but were still
positive in 25 and 9.4% of subjects with long-standing IDDM
(> 10 yr). In all study groups antibodies to GAD67 were only
detected in GAD65 antibody-positive sera. An immunotrapping
enzyme activity assay for GAD65 antibodies was positive in
64/75 (85.3%) of sera that were GAD antibody positive in the
immunoprecipitation test (r = 0.870, P < 0.0001). In two
(2.7%) sera GAD65 antibodies that blockGAD enzyme activity
were found. Our data suggest that antibodies to GAD65 but not
to GAD67 represent sensitive markers for preclinical and overt
IDDM. The immunotrapping assay here described represents a
valuable technique for specific and sensitive screening forGAD
antibodies. (J. Clin. Invest. 1993. 92:1394-1399.) Key words:
glutamic acid decarboxylase * autoantibodies * insulin-depen-
dent diabetes mellitus * islet cell antibodies
Introduction
Insulin-dependent diabetes mellitus (IDDM)' is strongly asso-
ciated with the appearance of islet cell-specific autoantibodies,
reflecting the autoimmune-mediated destruction ofthe pancre-
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atic beta cells. Cytoplasmic islet cell antibodies (ICA) as well as
antibodies to a 64-kD islet cell protein (64K) have been de-
tected in 70-90% of individuals before and at the time ofdiag-
nosis ofIDDM ( 1-4). In prospective studies only a subgroup
of ICA-positive nondiabetic individuals, especially those with
high ICA titers and complement-fixing ICA, developed IDDM
(5, 6). In first-degree relatives and ICA-positive nondiabetic
subjects antibodies to the 64K antigen were detected early in
the preclinical course of IDDM and were strongly correlated
with rapid progression to overt diabetes (7, 8). Therefore, the
accurate determination ofantibodies to the 64K antigen would
be of particular interest to identify subjects at high risk for the
development ofIDDM. A large-scale detection of64K antibod-
ies has been hampered by the laborious technique of the im-
munoprecipitation of [35S ] methionine-labeled islet cells prepa-
rations.
The target antigen ofthe 64K antibodies has been identified
as the enzyme glutamate decarboxylase (GAD), which synthe-
sizes y-aminobutyric acid (GABA) from glutamic acid (9).
GAD exists at least in two different isoforms with molecular
sizes of 65 kD (GAD65) and 67 kD (GAD67) encoded by two
distinct genes (10, 11). It was shown that GAD65 corresponds
to the 64K antigen and both isoforms are recognized by sera
from patients with IDDM ( 12, 13). Population-based data on
the frequency ofantibodies to human GAD67 are scanty. Thus,
the importance of antibodies to GAD67 for IDDM is still un-
clear.
Because both isoforms ofGAD are expressed in brain neu-
rons ( 12, 13 ) several studies used brain preparations to deter-
mine antibodies toGAD by an immunotrapping enzyme activ-
ity assay (ITA) ( 14-16). In contrast to 64K antibodies, anti-
bodies to GAD, as measured in the ITA, were detected in only
25-37% of newly diagnosed patients with IDDM. It has been
suggested that these controversial data might be due to differ-
ences in the sensitivity of the assays or that only a part of the
immunoreactivity to the 64K islet protein is directed to GAD.
In none ofthese reports has a direct comparison ofthe immuno-
precipitation test and the ITA been performed to address this
question.
In the present study human recombinant GAD expressed
in the baculovirus system was used to determine autoantibod-
ies to GAD65 and GAD67. We analyzed for the first time the
prevalence ofantibodies to GAD65 and GAD67 in individuals at
high risk for IDDM, at the onset ofthe disease, and in patients
with a long duration ofIDDM. In our approach we compared
the results of the conventional immunoprecipitation test with
the GAD immunotrapping enzyme activity assay in individual
sera. This made it possible for us to determine antibodies which
block GAD enzyme activity and evaluate the diagnostic value
of the different immunoassays regarding the detection of anti-
bodies to GAD.
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Methods
Human sera. We studied sera from 50 patients with IDDM, obtained
within the first month of diagnosis, and 77 sera from patients with a
duration ofIDDM from 0.5 to 40 yr. In addition, subjects at high risk
for the development ofIDDM were evaluated for GAD antibodies. We
assayed GAD antibodies in 11 persistently ICA-positive nondiabetic
schoolchildren without a family history of IDDM from the Ulm-
Frankfurt population study (8, 17, 18) and 50 nondiabetic first-degree
relatives of patients with IDDM. Among the 50 relatives, 15 were posi-
tive for circulating ICA at high level (> 40 JDF-U). 60 ICA-negative
sera from normal individuals without a family history for IDDM were
used as control samples. The sera were coded, stored at -20'C, and
tested in a blinded way in each of the assays. Informed consent was
obtained from all patients and control subjects.
Detection ofcytoplasmic ICA. Cytoplasmic ICA were analyzed by
the indirect immunofluorescence tests on cryostat sections of human
pancreas from an organ donor with blood group 0 ( 19). ICA were
expressed in Juvenile Diabetes Foundation (JDF) Units (IDW ICA
Proficiency Program, Lab ID No 1 16). The detection limit ofthe assay
in our laboratory was 5 JDF-U.
Antigen expression and preparation. GAD65 and GAD67 cDNA
clones were constructed by inserting full-length human GAD65 and
GAD67 cDNAs into the baculovirus vector pVL1393 (Invitrogen, San
Diego, CA). The cDNA clones were cotransfected with the wild-type
Autographa californica virus and the recombinant baculovirus clones
were isolated as described (20). Spodopterafrugiperda (Sfi9) cells were
infected with the recombinant baculovirus clones and cultured in
SF900 medium (Gibco Laboratories, Grand Island, NY) supple-
mented with 0.04% FCS for 48 h. Then cellswere harvested and homog-
enized in 20 mM potassium phosphate, pH 7.0; 2 mM EDTA; 2 mM
PMSF; 5 Ag/ml Leupeptin; 1 mM 2-aminoethylisothiouronium bro-
mide (AET); and 0.2 mM pyridoxal 5-phosphate (PLP) (buffer A).
For immunoprecipitation experiments infected Sf9 cells were cultured
in Grace's medium (Gibco Laboratories) for 36 h, labeled with [35S]-
methionine (200 MCi/5 X 106 cells) for 6 h, and homogenized in buffer
A. The homogenates were centrifugated at 33,000 g for 30 min to
separate the soluble cytosolic fraction in the supernatant and the partic-
ulate fraction in the pellet. Cell pellets were stored at -80°C until
further preparation.
Immunoprecipitation test (IPT). The IPT was performed with
minor modifications as described previously (8). The particulate frac-
tions of [ 31S ] methionine-labeled Sf9 cells were resuspended in 20 mM
potassium phosphate, 150 mM NaCl, pH 7.2; 2 mM EDTA; 2 mM
PMSF; 1% Trasylol; and 1% Triton X-100 for 2 h at 4°C followed by
centrifugation at 33,000 g for 30 min to obtain the membrane fraction
(MF) in the supernatant. MFs containing equal amounts of radiola-
beled GAD65 or GAD67 were incubated with a pool of normal human
serum (25 gl/ 100 ,l lysate, equivalent to 5 X 105 infected SO' cells) for
6 h and then preabsorbed with protein A-Sepharose (Pharmacia Inc.,
Freiburg, Germany). 100 Ml of the precleared extracts were precipitated
with 25 Ml test serum, followed by an adsorption of the immunocom-
plexes on protein A-Sepharose. After extensive washing the bound
proteins were eluted with 65 mM Tris/HCI, pH 6.8; 2% SDS; and 5%
mercaptoethanol and analyzed by fluorography. Fluorograms were an-
alyzed by densitrometry (LKB Ultroscan; Pharmacia Inc.). In each
experiment a positive and a negative reference serum were included as
internal controls. Peak areas compared with the positive serum were
taken as a measure of the GAD antibody level and expressed in percent
of the positive standard serum. Values above mean + 3 SD of 60 con-
trol subjects were considered positive. Using this assay in the First
GAD Antibody Workshop, we achieved a specificity of 100%, asensitiv-
ity of 83.3%, and a validity of 87.5%.
ITA. The particulate fraction of Sf9 cells expressing GAD65 was
resuspended in buffer A, pH 7.0, supplemented with 1% Triton X-100
for 2 h at 4°C. After centrifugation at 33,000 gfor 30 min, the superna-
tant was used to perform the ITA. 100 Ml of serum were incubated with
200 Ml reconstituted protein A-Sepharose beads for 2 h at 20'C. The
beads were washed four times with 50 mM potassium phosphate, pH
7.0; 1 mM EDTA; 1 mM AET; 0.2 mM PLP; and 0.5% Triton X-100,
400 AI ofMF (corresponding to a GAD activity of0.5 mU) was added
for 12 h at 4VC. After another washing step, 400 AI 50 mM potassium
phosphate buffer, pH 7.0, with 1 mM EDTA, 1 mM AET, 1 mM
glutamic acid, 0.2 mM PLP (buffer B) was added, and the samples
were divided into two aliquots and the precipitated enzymatic GAD
activity was determined. The immunotrapped GAD activity was calcu-
lated by subtracting the background counts using PBS instead ofserum
and was expressed in AU immunotrapped by 50 ,A serum. Sera were
considered GAD antibody positive if the immunoprecipitated GAD
activity was above the mean + 3 SD of 60 control subjects.
Determination ofGAD enzyme activity. GAD activity was analyzed
using a modification of the protocol described by Miller et al. (21 ).
Aliquots of homogenates or immunocomplexes were diluted in buffer
B to a total volume of 200 AL with a final concentration of 1 mM/liter
L-glutamic acid and a specific radioactivity of L[ 1- '4C]glutamic acid
(Amersham Corp., Braunschweig, Germany) of 500 MCi/mmol for
assaying ofGAD activity in the cell extracts and 1,000 ,Ci/mmol in
the ITA, respectively. After adding the reaction mixture into glass
tubes, a filter paper soaked with 50 Al 1 M hyamine hydroxide was
placed into the tubes. The tubes were closed and incubated for 1 h at
37°C. The reaction was stopped by injecting 1 ml 5 N sulphuric acid
followed by an equilibration period of 1 h to allow complete adsorption
of released '4CO2. Then the "4CO2 trapped to the filter paper was mea-
sured in a liquid scintilation counter. GAD enzyme activity was ex-
pressed in U/mg protein. One unit was defined as the formation of 1
Mmol C02/min under standard assay conditions.
Statistical analysis. The significance of differences between obser-
vations was tested using the Wilcoxon test, the chi-square test with
Yates' correction, or the Fisher's exact test, where appropriate. The
correlations ofantibody levels were tested by linear-regression analysis.
Results
Autoimmunity to GAD in IDDM is mainly directed to GAD65.
Human recombinant GAD65 and GAD67 were highly ex-
pressed in a baculovirus system. The enzymatic activity of
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Figure 1. Immunoprecipitation of [35S]methionine-labeled human
recombinant GAD65 and GAD67. Membrane fractions of GAD65
(lanes 1-4) and GAD67 (lanes 5-8) were immunoprecipitated with
two sera from newly diagnosed IDDM patients (patient 1, lanes I
and 6, patient 2, lanes 2 and 5) and a serum from a control subject
(lanes 3 and 7). Patient 1 was positive for antibodies to GAD65 but
negative for antibodies to GAD67, patient 2 had antibodies to GAD65
and GAD67. As positive controls the immunoprecipitation with the
mouse monoclonal antibody GAD 1 (lane 4) and the rabbit anti-
serum K-2 (lane 8) are shown. Molecular weight markers (Mr
x 10-3) are indicated on the left margin.
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Table I. Characterization ofStudy Groups
Sex Age
Number of
Study groups sera tested Female Male Mean Median Range
Control subjects 60 34 26 23.5 22 8-38
High risk subjects
First degree relatives
ICA negative 35 17 18 20.0 21 4-37
ICA positive 15 9 6 25.0 23 15-59
ICA + schoolchildren 11 4 7 12.0 13 8-15
Patients with IDDM
New onset IDDM 50 23 27 25.1 25 5-41
Duration ofIDDM
0.5-2 yr 21 9 12 22.2 24 6-38
2-10 yr 24 12 12 26.0 29 3-47
>10 yr 32 15 17 35.1 36 18-61
crude lysates ofS9 cells expressing GAD65 and GAD67 was 155 bles I and II. In the immunoprecipitation test, antibodies to
and 169 mU/mg protein, respectively. Both GADs were im- GAD65 were present in 35 (70%) of50 newly diagnosed IDDM
munoprecipitated by IDDM sera. Recombinant GAD65 was patients, whereas GAD67 antibodies were detected in only 9
recognized by the mouse monoclonal antibodies GAD1 (18%) subjects (P < 0.00001). In addition, antibodies to
(ATTC no. HB 184; reference 22) and recombinant GAD67 GAD67 were observed only in GAD65-positive sera. At the on-
was precipitated by the K-2 antiserum (23), which binds to the set of IDDM, ICA were positive in 38 (76%) sera (mean ICA
67-kD isoform ofGAD (Fig. 1). The characterization ofstudy level 157±304 JDF-U, range 10-1,280). No correlation could
groups and the prevalences of antibodies to GAD65, GAD67, be demonstrated between the levels of ICA and antibodies to
and ICA in the different study groups are summarized in Ta- GAD65 or GAD67 . Out of 12 ICA-negative sera from patients
Table II. Prevalence ofAntibodies to GAD65 and GAD67 and Islet Cell Antibodies within the Study Groups
Immunotrapping
Immunoprecipitation test assay
Number of GAD65 GAD67 GAD65
Study groups sera tested ICA antibody antibody antibody
JDF-U
Control subjects 60 0 0 0 0
High risk subjects
First degree relatives
ICA positive 15 15 13 (86.7%) 5 (33.3%) 12 (80.0%)
(331±211) (143±85) (102±105) (117±89)
ICA negative 35 0 1 (2.9%) 0 0
(23)
ICA + schoolchildren 11 11 6 (54.6%) 0 6 (54.6%)
(52±45) (34±20) (19±15)
Patients with IDDM
New onset IDDM 50 38 (76.0%) 35 (70.0%) 9 (18.0%) 27 (54.0%)
(157±304) (74±66) (64±72) (56±61)
Duration ofIDDM
0.5-2 yr 21 8 (38.1%) 7 (33.3%) 3 (14.3%) 6 (28.6%)
(117±103) (131±90) (14/23/210) (146±86)
2-10 yr 24 6 (25.0%) 5 (20.8) 2 (8.3%) 5 (20.8%)
(90±56) (76±99) (16/100) (88±90)
>10 yr 32 2 (9.5%) 8 (25.0%) 3 (9.4%) 8 (25.0%)
(60/160) (82±79) (13/67/136) (50±60)
Results obtained with the ITA are expressed in MU of enzyme activity immunotrapped by 50 Ml serum; values > 6.7 MU are taken as positive.
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GAD antibody levels in the IPT are demonstrated as % of the GAD antibody positive reference serum. Antibody levels (mean + SD) are given
in parentheses (if less than four subjects were positive the measured values are indicated).
with new onset of IDDM, GAD65 and GAD67 antibodies were
found in 7 (58.3%) and 1 (8.3%) subjects, respectively. Thus,
26/50 (52%) of the patients had ICA as well as antibodies to
GAD65 and 45 / 50 (90%) were found to be positive for one of
these markers. Among the 60 controls neither antibodies to
GAD65, antibodies to GAD67, or ICA were detected.
The prevalence of each of the antibody specificities tested
declined after the onset of IDDM (Table II). After 0.5-2 yr,
antibodies to GAD65 as well as ICA were decreased compared
with newly diagnosed patients with IDDM (P < 0.05). IDDM
patients tested up to 10 yr after onset of IDDM exhibited a
highly significant reduction ofantibodies to GAD65 and ICA (P
< 0.0005). In long-term diabetic patients ( 11-40 yr), the fre-
quency of antibodies to GAD65 (8/ 32, 25.0%) was slightly in-
creased compared with the IDDM patients 2-10 yr after onset
of IDDM. The prevalance of antibodies to GAD67 declined
from 18% at diagnosis to 9.4% after long duration of IDDM,
but this did not reach the level of significance.
High prevalance of GAD antibodies in subjects with in-
creased risk for IDDM. 6 of 11 (54.5%) nondiabetic individ-
uals with persistent ICA (mean 52±45 JDF-U, range 10-160)
without a family history of IDDM possessed antibodies to
GAD65. All of these six sera had been found 64K antibody
positive in the IPT using labeled islets (8). 13 (86.7%) of 15
first-degree relatives with ICA levels > 40 JDF-U (mean
331±211 JDF-U, range 80-640) had antibodies to GAD65,
whereas only 5 (33.3%) ofthem were GAD67 antibody positive
(P < 0.05). The level ofthe GAD65 antibodies ( 143±85%) was
significantly increased compared with new onset IDDM pa-
tients (74±66%) (P < 0.005). In 1 of 35 (2.9%) ICA-negative
relatives, antibodies to GAD65 were observed. Antibodies to
GAD67 were only detected in GAD65 antibody-positive sera.
Antibodies to GAD67 were negal
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The ITA reveals GAD antibodies ofhigh specificity and sen-
sitivity. All sera from the different study groups were tested in
our newly developed ITA using recombinant GAD65. The
mean + 1 SD of the immunotrapped GAD activity of 60 con-
trol subjects was 2.32 + 1.46 (range 0.44-5.77 AU). Binding of
> 6.7 MU (mean + 3 SD) was considered as immunotrapped
GAD65 antibody positive. The intra- and interassay coefficients
of variation were 10.2% (n = 8) and 15.7% (n = 8), respec-
tively. Antibodies to GAD65, detected by the ITA were found
in 64 of 75 (85.3%) of the GAD65 antibody-positive subjects,
as characterized in the IPT (Table 1). The mean level of the
positive subjects was 71±75 uU (range 6.8-277.0 ,U). There
was a strong correlation between the levels ofGAD65 antibod-
ies determined in the IPT and the level of immunotrapped
GAD activity (Fig. 2) (r = 0.870, P < 0.0001). None of the
GAD65 antibody-negative subjects or of the normal controls
exceeded the normal range (mean + 3 SD of controls). Com-
pared with the conventional IPT as the gold-standard tech-
nique, the ITA achieved values of 100% for specificity and
87.2% for sensitivity.
GAD-blocking antibodies appear in only a minority ofindi-
viduals. GAD antibodies that block the enzyme activity were
detected by analyses ofthe results ofthe IPT compared with the
ITA in individual sera. Regarding 11 GAD65 antibody-positive
sera, which were negative in the ITA, 9 turned out to be just
weakly GAD65 antibody positive (GAD65 antibody level 13-
17% ofthe reference serum) (Fig. 2). Thus, only 2 of75 (2.7%)
GAD65 antibody-positive sera may possess high titers ofGAD
antibodies that inhibited the enzyme activity.
Discussion
tive in all ICA-negative first-de- Antibodies to the 64K islet cell protein have been described as
)sitive schoolchildren. an early and reliable serological marker to predict future devel-
opment of IDDM in nondiabetic individuals. The identifica-
tion of the 64K protein as GAD and the recognition of at least
two isoforms have raised the question as to which isoform
would be the major antigen in the natural history ofIDDM. To
address this question we expressed human GAD65 and GAD67
in the baculovirus system to produce a homogeneous source of
native antigens. This allowed us to overcome the disadvantages
of the antigen shortage, differences in the cell preparation, and
antigen purity, which were critical to the conventional IPT
using isolated islets.
The observed prevalence of 86.7% of antibodies to GAD65
in ICA-positive relatives and 70% in patients with recent onset
ofIDDM was similar to the frequency of64K antibodies using
labeled islets (4, 24). In addition, we detected antibodies to
GAD65 in all 64K antibody-positive schoolchildren (8). These
findings support the contention that GAD65 is identical to the
64K islet cell protein (9, 13). Consistent with studies suggest-
ing that antibodies to the 64K antigen indicate an increased
50 100 200 300 risk for the development ofIDDM (7), we found that three of
lies (% reference serum) the six GAD65 antibody-positive schoolchildren developed
overt IDDM after a follow-up of 16-30 mo (8). In our studyLnd the conventional IFT for the the prevalence and levels ofantibodies to GAD65 were higher in
nonstrated. The levels of GAD an- ICA-positive relatives compared with patients with new onset
s immunotrapped enzyme activity IDDM. This suggests that the autoimmune reaction to GAD
he immunoprecipitation test are appears at an early stage preceeding the diagnosis of IDDM.
positive reference serum. The Until now, only limited data are available on the presence
3 SD of healthy controls (6.7 ,uU). of antibodies to GAD67 in IDDM. We detected antibodies to
GAD67 in only 33.3% of ICA-positive relatives and in 18% of
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patients with newly diagnosed IDDM. The surprising differ-
ence in the antibody reactivity to GAD65 and GAD67 empha-
sizes the relevance ofthe diversity ofthe two isoforms ofGAD.
The amino acid sequence identity between human GAD65 and
GAD67 is 65%, with the highest diversity for the amino-ter-
minal 120 amino acids ( 1). This may either suggest that the
majority of antibodies to GAD are primarily directed to the
amino terminus or the diversity of the amino acid sequence
between GAD65 and GAD67 leads to conformational changes
of the GAD protein. The importance ofthe three-dimensional
structure of GAD is emphasized by the fact that most of the
IDDM sera do not react with denaturated GAD65 (9) . In con-
trast to the present data, Kaufman et al. ( 13 ) and Deaizpurua
et al. (25) reported on antibodies to GAD67 in 9 of 12 and in 7
of 9 preclinical subjects as well as in 3 of 3 and in 6 of 13
patients with IDDM, respectively. Various explanations could
be found for this disagreement. First, these authors used bacte-
rially expressed rat or mouse GAD67. Despite a high homology
of rat, mouse, and human GAD67 ( 11 ) the discrepancy could
be due to the species differences, since different antigenic en-
zyme forms of GAD have been described (26, 27). Second,
Kaufman et al. ( 13) used a mixture of [35S] methionine-labeled
GAD65 and GAD67 in the IPT, which could lead to unspecific
precipitation ofGAD isoforms. There is evidence that mono-
clonal GAD antibodies that recognize only GAD65 coprecipi-
tate both isoforms from brain preparations (24, 28). This sug-
gests that GAD65 and GAD67 can tightly associate, probably by
forming heterodimers. The higher frequency of antibodies to
GAD67 observed by Diaizpurua et al. (25) may be explained by
the application of an ELISA for the detection of the autoanti-
bodies. International workshops on the standardization of in-
sulin autoantibody measurement have clearly shown that
solid-phase and fluid-phase assays detect different antibody
populations with different affinities (29). Insulin autoantibod-
ies were more frequently detectable by ELISA but antibodies
measured by fluid-phase assays were much better correlated
with IDDM (29). According to our data, GAD67 is only a
minor target antigen in IDDM. This is in line with data suggest-
ing that human islets express only GAD65 but not GAD67 ( 11 ).
The autoimmune reaction in IDDM may be primarily directed
against GAD65 and subgroups ofthe polyclonal natural autoan-
tibodies could recognize common epitopes ofthe two isoforms
of GAD. This assumption is supported by the fact that our
human monoclonal GAD antibodies (MICA 1-6) derived
from a patient with newly diagnosed IDDM all recognized only
the GAD65 isoform (30). Furthermore, in the present study,
antibodies to GAD67 were restricted to patients with GAD65
immunoreactivity. Direct epitope studies will be required to
fully support this hypothesis.
Analogous to ICA, the prevalence of antibodies to GAD65
and GAD67 declined in the first years after the onset ofIDDM.
This has also been shown for 64K antibodies (31 ). However, in
our study, antibodies to GAD65 were still detectable in 25% of
subjects with a long duration ofIDDM. As initially reported by
Kaufman et al. ( 13), we here observed that six ofeight patients
with long-standing IDDM and antibody reactivity to GAD65
had a peripherial diabetic neuropathy (data not shown). The
high frequency ofGAD antibodies in these patients could be
explained by the reappearance ofantibodies toGAD caused by
a repeated presentation ofGAD to the immune system by the
affection of GABA synthesizing neurons during the develop-
ment of diabetic neuropathy (32).
After the identification of GAD as a target antigen in
IDDM, antibodies to GAD were detected in several studies by
measuring the immunotrapping enzyme activity. The preva-
lence of antibodies to GAD was reported to be as low as 25-
38% using rat (14), pig (15), or human brain preparations
( 16). On the basis ofthe studies mentioned above, it could not
be decided whether the low prevalence ofantibodies toGAD in
the ITA compared with the IPT is due to differences in the
source of antigen or to the lower sensitivity of the ITA. In our
newly developed ITA using human GAD65, we can detect anti-
bodies in > 85% of sera that were positive in the IPT. For the
first time we demonstrate a strongly positive correlation be-
tween the level of antibodies in both assays. With this new
assay the ITA achieved a 100% specificity and a high sensitivity
that was only slightly decreased compared with the standard
IPT. It is important to emphasize that out of75 GAD antibody
positive sera only 2 sera had high levels in the IPT, being repeat-
edly negative in the ITA. This suggests the presence ofGAD
binding antibodies inhibiting the GAD enzyme activity. Fur-
thermore, nine sera with low antibody levels in the IPA were
negative in our ITA. These negative results may be explained
by the lower sensitivity ofthe measurement ofenzyme activity
in the ITA compared with the fluorography technique. As we
cannot exclude the presence of antibodies that block GAD en-
zyme activity in these sera, our data at least indicate that GAD-
blocking antibodies are only present in a minority of patients
with IDDM.
In conclusion, antibodies to GAD65 are valuable serological
markers for preclinical and overt IDDM, whereas antibodies to
GAD67 may be of minor importance. Because GAD-blocking
antibodies appear only in a minority of patients with IDDM,
the ITA represents a valuable tool for the detection ofantibod-
ies to GAD with the advantage ofeasy performance and quan-
titative measurement ofthe autoantibodies. The availability of
human recombinant GAD facilitate specific and sensitive
screening for antibodies to GAD on large scale and may be
useful to determine the role of GAD in the development of
IDDM.
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